Romvimza (vimseltinib) — Highmark
symptomatic tenosynovial giant cell tumor (TGCT) where surgical resection may cause worsening functional limitation or severe morbidity
Initial criteria
- age ≥ 18 years
- diagnosis of symptomatic TGCT (ICD-10: D21, D48.1, M12, M65)
- prescriber attests that surgical resection may cause worsening functional limitation OR severe morbidity
Reauthorization criteria
- prescriber attests member is tolerating therapy
- prescriber attests member has experienced disease improvement OR delayed disease progression
Approval duration
12 months